Combivent Respimat (Ipratropium/Albuterol Sulfate) Patent Expiration, LOE Window & CMS Spending

Combivent Respimat (Ipratropium/Albuterol Sulfate) by Boehringer Ingelheim: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $495.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN021747 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$495.0M
2024 Medicare Part D Spend$387.9M
2024 Medicaid Spend$107.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.